We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
-0.85%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$471M
AUM Growth
-$63.9M
Cap. Flow
-$5.68M
Cap. Flow %
-1.2%
Top 10 Hldgs %
58.75%
Holding
54
New
6
Increased
11
Reduced
10
Closed
15

Top Buys

Rank Stock Value
1
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$25.5M
2
DNA icon
Ginkgo Bioworks
DNA
+$11M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$7.95M
4
MRUS
Merus
MRUS
+$6.15M
5
HYPR icon
Hyperfine
HYPR
+$6.04M

Top Sells

Rank Stock Value
1
BBIO icon
BridgeBio Pharma
BBIO
+$7.76M
2
ADMS
Adamas Pharmaceuticals
ADMS
+$7.17M
3
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$6.98M
4
CLDX icon
Celldex Therapeutics
CLDX
+$6.14M
5
SMLR
Semler Scientific
SMLR
+$6M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CDXS icon
1
Codexis
CDXS
$182M
$42.1M 8.92%
1,345,000
– –
OCUL icon
2
Ocular Therapeutix
OCUL
$2.38B
$41.6M 8.83%
5,974,800
-505,200
-8% -$3.92M
CMRX
3
DELISTED
Chimerix, Inc.
CMRX
$35.9M 7.61%
5,580,000
+550,000
+11% +$3.3M
CLDX icon
4
Celldex Therapeutics
CLDX
$3.18B
$32.6M 6.92%
844,000
-141,000
-14% -$6.14M
HROW icon
5
Harrow
HROW
$1.44B
$28.4M 6.02%
3,285,000
– –
CYTK icon
6
Cytokinetics
CYTK
$10.8B
$26.4M 5.61%
580,000
– –
CRNX icon
7
Crinetics Pharmaceuticals
CRNX
$9B
$20.6M 4.36%
724,400
+322,287
+80% +$7.95M
TARA icon
8
Protara Therapeutics
TARA
$236M
$18M 3.82%
2,650,000
+91,528
+4% +$631K
SMLR
9
DELISTED
Semler Scientific
SMLR
$15.8M 3.34%
172,000
-53,566
-24% -$6M
STXS icon
10
Stereotaxis
STXS
$147M
$15.7M 3.32%
2,526,500
– –
KROS icon
11
Keros Therapeutics
KROS
$223M
$15.5M 3.3%
265,750
-86,750
-25% -$4.33M
KNSA icon
12
Kiniksa Pharmaceuticals
KNSA
$6.23B
$12.1M 2.56%
1,025,000
-285,000
-22% -$3.5M
PTGX icon
13
Protagonist Therapeutics
PTGX
$9.67B
$11.7M 2.48%
342,000
+11,778
+4% +$372K
PRQR icon
14
ProQR Therapeutics
PRQR
$327M
$11.5M 2.44%
1,435,510
+11,310
+0.8% +$86.1K
ETON icon
15
Eton Pharmaceutcials
ETON
$1.79B
$10.2M 2.17%
2,385,000
-703,100
-23% -$3.36M
STRO icon
16
Sutro Biopharma
STRO
$353M
$10.1M 2.15%
68,000
+14,220
+26% +$2.55M
MRUS
17
DELISTED
Merus
MRUS
$10.1M 2.14%
317,800
+217,550
+217% +$6.15M
LRMR icon
18
Larimar Therapeutics
LRMR
$421M
$9.53M 2.02%
883,602
+50,795
+6% +$565K
FBIO icon
19
Fortress Biotech
FBIO
$93.4M
$9.38M 1.99%
250,000
– –
RETA
20
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$8.7M 1.85%
+330,000
New +$25.5M
TCON
21
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$8.46M 1.79%
152,750
+26,831
+21% +$1.71M
DNA icon
22
Ginkgo Bioworks
DNA
$489M
$7.73M 1.64%
+23,245
New +$11M
PCVX icon
23
Vaxcyte
PCVX
$9.1B
$7.51M 1.59%
315,800
-37,600
-11% -$874K
MGNX icon
24
MacroGenics
MGNX
$260M
$7.42M 1.57%
462,000
– –
XOMA
25
DELISTED
Xoma
XOMA
$7.05M 1.5%
338,350
– –
1
2 3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q4 2021 Portfolio in Review

As of Q4 2021, Opaleye Management held 54 positions worth $471M, down 12% from $535M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Opaleye Management's Q4 2021 filing shows 6 new, 11 increased, 10 reduced and 15 closed positions. Its largest new stake was Reata Pharmaceuticals, Inc. Class A Common Stock: 330,000 shares worth $8.7M. The largest sale was BridgeBio Pharma, an estimated $7.76M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

  • Opaleye Management's largest Q4 2021 buy was Reata Pharmaceuticals, Inc. Class A Common Stock: 330,000 shares worth $8.7M.
  • Opaleye Management added most to Crinetics Pharmaceuticals in Q4 2021, an estimated $7.95M increase.
  • Opaleye Management's biggest Q4 2021 reduction was BridgeBio Pharma, cutting an estimated $7.76M.
  • Opaleye Management fully exited Adamas Pharmaceuticals in Q4 2021, selling an estimated $7.17M.
  • Opaleye Management's ten largest holdings make up 59% of its $471M portfolio in Q4 2021.
  • Opaleye Management opened 6 new positions and closed 15 in Q4 2021.
  • Opaleye Management's portfolio value fell 12% quarter-over-quarter to $471M.

Based on Opaleye Management's 13F filing for Q4 2021, filed 14 Feb 2022.